Table 1. Baseline characteristics for Cohorts 1 and 2.
| Characteristic |
Number of patients (%) |
|
|---|---|---|
| Cohort 1 (N=1900) | Cohort 2 (N=887) | |
| Age, years | ||
| ⩽65 | 1009 (53.1%) | 465 (52.4%) |
| >65 | 891 (46.9%) | 422 (47.6%) |
| Sex | ||
| Male | 1137 (59.9%) | 529 (59.6%) |
| Female | 763 (40.2%) | 358 (40.4%) |
| ISS stage | ||
| I | 481 (25.0%) | 235 (26.5%) |
| II | 653 (34.4%) | 377 (42.5%) |
| III | 501 (26.4%) | 178 (20.1%) |
| Missing | 265 (14.0%) | 97 (10.9%) |
| High-risk CA by iFISH | ||
| Absent | 1071 (56.4%) | 346 (39.0%) |
| Present | 297 (16.0%) | 126 (14.2%) |
| Missing | 532 (28.0%) | 415 (46.8%) |
| LDH level | ||
| Normal | 1258 (66.2%) | 673 (75.9%) |
| Elevated | 268 (14.1%) | 182 (20.5%) |
| Missing | 374 (19.7%) | 32 (3.6%) |
| Treatment | ||
| IMIDs | 1304 (68.6%) | 458 (51.6%) |
| PIs | 877 (46.2%) | 196 (22.1%) |
| ASCT | 247 (13%) | 0 (0%) |
| Other | 0 (0%) | 233 (26.3%) |
| Missing | 9 (0.47%) | 0 (0%) |
Abbreviations: ASCT, autologous stem cell transplant; CA, chromosomal abnormalities; iFISH, fluorescent in situ hybridization; IMID, immunomodulatory drugs; ISS, International Staging System; LDH, lactate dehydrogenase; PIs, proteasome inhibitors.